SGLT2 Inhibition in Diabetes and Heart Failure
NCT02862067 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18
Last updated 2018-07-16
Summary
To determine the effects of SGLT2 inhibition with empagliflozin on cardio-respiratory fitness in patients with systolic heart failure.
Conditions
- Diabetes Mellitus, Type 2
- Heart Failure, Systolic
Interventions
- OTHER
-
Assessment of cardiorespiratory fitness
Assessment of cardiorespiratory fitness
Sponsors & Collaborators
- collaborator OTHER
-
Virginia Commonwealth University
lead OTHER
Principal Investigators
-
Salvatore Carbone, PhD, MS · Virginia Commonwealth University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-31
- Primary Completion
- 2018-01-16
- Completion
- 2018-01-16
Countries
- United States
Study Locations
More Related Trials
-
Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure
NCT06140251 ·Status: RECRUITING
-
Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes
NCT02397421 ·Status: COMPLETED ·Phase: PHASE4
-
Ketones, SGLT2, HFrEF
NCT06229678 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Randomized Trial of SGLT2i in Heart Transplant Recipients
NCT06625073 ·Status: RECRUITING ·Phase: PHASE4
-
SGLT2 Inhibition and Left Ventricular Mass
NCT02728453 ·Status: TERMINATED ·Phase: PHASE4
-
Canagliflozin and Myocardial Fibrosis
NCT05367063 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
NCT06055452 ·Status: RECRUITING ·Phase: PHASE4
-
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
NCT05139914 ·Status: TERMINATED ·Phase: PHASE4
-
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling
NCT05993897 ·Status: UNKNOWN ·Phase: NA
-
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
NCT03485092 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
NCT04071626 ·Status: TERMINATED ·Phase: PHASE4
-
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT03249506 ·Status: COMPLETED
-
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
NCT06201000 ·Status: RECRUITING
-
Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
NCT02998970 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
NCT06901609 ·Status: ACTIVE_NOT_RECRUITING
-
Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF
NCT04739215 ·Status: UNKNOWN ·Phase: PHASE4
-
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
NCT06284850 ·Status: RECRUITING
-
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
NCT02973477 ·Status: COMPLETED ·Phase: PHASE4
-
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
NCT06825156 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 ·Status: COMPLETED
-
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
NCT06249945 ·Status: RECRUITING ·Phase: PHASE4
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
NCT07273838 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
NCT06260059 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients
NCT06585761 ·Status: RECRUITING
-
Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
NCT05194592 ·Status: UNKNOWN ·Phase: PHASE4